Nexus Pharmaceuticals recently announced their investment in building a sterile injectable manufacturing facility in Pleasant Prairie, Wisconsin. The new 100,000 square foot facility will be design by IPS, with Turner Construction providing construction management services. The facility will support the Wisconsin economy with 77 jobs in the field of high-tech manufacturing and science by 2022.
The initial phase 1 investment of $85m will support a new, three-story manufacturing facility with cutting edge technology including an advanced isolator system for maximum product protection and sterility; reducing the risk of contamination. The facility will also include multiple lyophilization (freeze-drying) machines to support production of Nexus’ current portfolio and pipeline of generic and specialty injectable drugs.
The IPS project team from our Kansas office, news and media outlets, and Wisconsin Gov. Tony Evers were on hand for the project announcement in Kenosha County.
The first phase of the project will begin in August 2019 and is to be completed by 2021. Production is expected to begin in 2022.
View the full press release on Nexus’ website.